Benefits and Harms of Doxycycline Treatment for Gulf War Veterans' Illnesses: A Randomized, Double-Blind, Placebo-Controlled Trial

Established in 1927 by the American College of Physicians

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

Benefits and Harms of Doxycycline Treatment for Gulf War Veterans' Illnesses

A Randomized, Double-Blind, Placebo-Controlled Trial

View this table:

[in a new window]

Table 1. Secondary Outcome Measures

View larger version (37K):

[in a new window]

Figure 1. Progress of participants through the trial. *Of these participants, 15 returned for the 12-month visit and had 12-month data for the Physical Component Summary score, while the remaining 28 were considered to have had treatment failure for the primary outcome measure. ${dagger}$ Of these participants, 14 returned for the 12-month visit and had 12-month data for the Physical Component Summary score; treatment was considered to have failed in the remaining 35. GWVIs = Gulf War veterans' illnesses.

View this table:

[in a new window]

Table 2. Baseline Characteristics of Participants

View larger version (20K):

[in a new window]

Figure 2. Study participants who improved more than 7 units on the Veterans Short Form-36 Health Survey Physical Component Summary score at each rating period compared with baseline. Error bars represent 95% CIs.

View this table:

[in a new window]

Table 3. Comparison of Secondary Outcome Measures in the Doxycycline and Placebo Groups at 12 Months

View this table:

[in a new window]

Table 4. Adverse Events Considered Possibly or Definitely Related to the Study Drug